PharmiWeb.com - Global Pharma News & Resources

Press Releases

Date Title Company
09-Aug-2022 TransMed7, LLC Announces First Clinical Use of SpeedBird™ Breast Biopsy Devices for Commercial Launch Businesswire
09-Aug-2022 AdaptHealth Reports Second Quarter 2022 Results Businesswire
09-Aug-2022 ADC Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates Businesswire
09-Aug-2022 Akanda to Supply Cansativa with Premium Indoor Cannabis Flower Grown at its Sintra Facility in Portugal Businesswire
09-Aug-2022 BioXcel Therapeutics Reports Second Quarter 2022 Financial Results and Recent Operational Highlights BioXcel Therapeutics
09-Aug-2022 Resource Finder and May Parsons RN supporting international nurses to ‘arrive and thrive’ in the NHS Resource Finder Recruitment
09-Aug-2022 ‘The Year of the Wasp’ may cause increased fatalities in the UK London Medical Laboratory
09-Aug-2022 Inmagene and HUTCHMED Announce First Participant in Global Phase I Trial of IMG-004 Inmagene
09-Aug-2022 PureTech To Receive up to Approximately $115.4 Million from Sale of a Portion of Founded Entity Shares PureTech
09-Aug-2022 Moberg Pharma´s interim report January - June 2022 Moberg Pharma
09-Aug-2022 Genmab Improves Its 2022 Financial Guidance Genmab
09-Aug-2022 CYTENA Unveils New Generation of B.SIGHT, a Fully Automated Single-Cell Dispenser for Microorganisms CYTENA
09-Aug-2022 Global Food Allergen Testing Market 2022-2028: High Growth of Global Food Trade & Stringent Government Regulations Driving Sector - ResearchAndMarkets.com Businesswire
09-Aug-2022 2 Day Virtual Seminar: Risk Management of Raw Materials in a GMP Environment (August 29-30, 2022) - ResearchAndMarkets.com Businesswire
09-Aug-2022 The Global Biologics market is projected to grow at a CAGR of 8.82% By 2032: Visiongain Reports Ltd Visiongain Reports Limited
09-Aug-2022 La Comisión Europea aprueba IMBRUVICA® (ibrutinib) en un régimen de combinación de duración fija para pacientes adultos con leucemia linfocítica crónica (LLC) sin tratamiento previo Businesswire
09-Aug-2022 Europäische Kommission erteilt Zulassung für IMBRUVICA® (ibrutinib) als Kombinationspräparat mit fester Behandlungsdauer für erwachsene Patienten mit zuvor unbehandelter chronischer lymphatischer Leukämie (CLL) Businesswire
09-Aug-2022 La Commission européenne approuve IMBRUVICA® (ibrutinib) en association à durée fixe pour les patients adultes atteints de leucémie lymphoïde chronique (LLC) précédemment non traitée Businesswire
09-Aug-2022 Full Day Virtual Seminar on Fundamentals of Pharmacokinetics - ResearchAndMarkets.com Businesswire
09-Aug-2022 Full Day Virtual Seminar on Fundamentals of Toxicology - ResearchAndMarkets.com Businesswire